Free Trial
NASDAQ:ALEC

Alector (ALEC) Stock Price, News & Analysis

Alector logo
$3.94 +0.18 (+4.79%)
(As of 11/22/2024 ET)

About Alector Stock (NASDAQ:ALEC)

Key Stats

Today's Range
$3.75
$4.11
50-Day Range
$3.64
$6.14
52-Week Range
$3.49
$8.90
Volume
715,700 shs
Average Volume
627,120 shs
Market Capitalization
$385.86 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$20.67
Consensus Rating
Buy

Company Overview

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.

Alector Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
80th Percentile Overall Score

ALEC MarketRank™: 

Alector scored higher than 80% of companies evaluated by MarketBeat, and ranked 216th out of 960 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Alector has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Alector has only been the subject of 2 research reports in the past 90 days.

  • Read more about Alector's stock forecast and price target.
  • Earnings Growth

    Earnings for Alector are expected to grow in the coming year, from ($1.87) to ($1.81) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Alector is -2.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Alector is -2.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Alector has a P/B Ratio of 3.26. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Alector's valuation and earnings.
  • Percentage of Shares Shorted

    6.24% of the float of Alector has been sold short.
  • Short Interest Ratio / Days to Cover

    Alector has a short interest ratio ("days to cover") of 8.8.
  • Change versus previous month

    Short interest in Alector has recently decreased by 3.09%, indicating that investor sentiment is improving.
  • Dividend Yield

    Alector does not currently pay a dividend.

  • Dividend Growth

    Alector does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    6.24% of the float of Alector has been sold short.
  • Short Interest Ratio / Days to Cover

    Alector has a short interest ratio ("days to cover") of 8.8.
  • Change versus previous month

    Short interest in Alector has recently decreased by 3.09%, indicating that investor sentiment is improving.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Alector this week, compared to 2 articles on an average week.
  • Search Interest

    1 people have searched for ALEC on MarketBeat in the last 30 days.
  • MarketBeat Follows

    Only 1 people have added Alector to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Alector insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $232,883.00 in company stock.

  • Percentage Held by Insiders

    Only 9.10% of the stock of Alector is held by insiders.

  • Percentage Held by Institutions

    85.83% of the stock of Alector is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Alector's insider trading history.
Receive ALEC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alector and its competitors with MarketBeat's FREE daily newsletter.

ALEC Stock News Headlines

Alector’s Strategic Advances in Immuno-Neurology
Alector Secures Funding to Advance Clinical Trials
I've got news for you…
Today, I’m doing something I thought I’d never do… Especially since I’m not normally a “swing for the fences” type of trader. But I’ve been quietly testing a new type of trade for a while now… And the returns are too good not to share with you. Take a look… I can’t guarantee results or against losses, but if you want to discover how I’ll target the triple return before the end of the week
Stifel Nicolaus Sticks to Its Buy Rating for Alector (ALEC)
See More Headlines

ALEC Stock Analysis - Frequently Asked Questions

Alector's stock was trading at $7.98 at the beginning of the year. Since then, ALEC shares have decreased by 50.6% and is now trading at $3.94.
View the best growth stocks for 2024 here
.

Alector, Inc. (NASDAQ:ALEC) released its quarterly earnings data on Wednesday, November, 6th. The company reported ($0.43) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.53) by $0.10. The company had revenue of $15.34 million for the quarter, compared to analyst estimates of $16.33 million. Alector had a negative trailing twelve-month return on equity of 108.77% and a negative net margin of 257.54%.

Alector subsidiaries include these companies: Alector LLC.

Alector (ALEC) raised $177 million in an initial public offering (IPO) on Thursday, February 7th 2019. The company issued 9,300,000 shares at a price of $18.00-$20.00 per share. Morgan Stanley, BofA Merrill Lynch, Cowen and Barclays served as the underwriters for the IPO.

Top institutional shareholders of Alector include FMR LLC (14.90%), State Street Corp (2.67%), Braidwell LP (2.20%) and Geode Capital Management LLC (1.94%). Insiders that own company stock include Polaris Venture Management Co, Arnon Rosenthal, Robert King, Sara Kenkare-Mitra, Gary Romano, Marc Grasso, Paula Hammond and Shehnaaz Suliman.
View institutional ownership trends
.

Shares of ALEC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Alector investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Enovix (ENVX), Meta Platforms (META), Rambus (RMBS), Saia (SAIA) and Tesla (TSLA).

Company Calendar

Last Earnings
11/06/2024
Today
11/24/2024
Fiscal Year End
12/31/2024
Next Earnings (Estimated)
2/25/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ALEC
Fax
N/A
Employees
270
Year Founded
2013

Price Target and Rating

Average Stock Price Target
$20.67
High Stock Price Target
$35.00
Low Stock Price Target
$12.00
Potential Upside/Downside
+424.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-130,390,000.00
Net Margins
-257.54%
Pretax Margin
-254.70%

Debt

Sales & Book Value

Annual Sales
$61.51 million
Book Value
$1.21 per share

Miscellaneous

Free Float
89,021,000
Market Cap
$385.86 million
Optionable
Optionable
Beta
0.66

Social Links

20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

This page (NASDAQ:ALEC) was last updated on 11/25/2024 by MarketBeat.com Staff
From Our Partners